Recent phosphoproteomic and genome-wide synthetic lethality strategies and chemogenetic drug screening have revealed novel targetable signaling vulnerabilities in GNAQ-driven uveal melanoma [6,7,9]. This evidence concerns the gene GNAQ and uveal melanoma.